Collaboration to develop rapid CJD (Creutzfeld Jakob disease) test:
This article was originally published in Clinica
Prionics, the Swiss firm that found an antibody specific to BSE and a form of Creutzfeld Jakob disease in humans (see Clinica No 782, p 21), is to team up with a US genomics firm to develop a blood test for the rogue prion protein that causes the diseases. Paradigm Genetics, of Research Triangle park, North Carolina, will work with Zurich-based Prionics on a rapid, high throughput test which could be used for human diagnostics within several years.
You may also be interested in...
Dispatches from a world turned upside down include FDA expressing confidence in Chinese manufacturers – to make their GDUFA payments; projections of drug shortages for ventilator patients; and the launch of new hydroxychloroquine studies.
A Phase III trial testing the antibody-drug conjugate sacituzumab govitecan was stopped early for efficacy, boding well for the BLA pending at the US FDA.
Deal Snapshot: Six companies seek to collect convalescent plasma from COVID-19 survivors to quickly develop hyperimmune immunoglobulin therapy for serious complications of the virus.